Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Am J Physiol Gastrointest Liver Physiol ; 326(2): G120-G132, 2024 02 01.
Article in English | MEDLINE | ID: mdl-38014444

ABSTRACT

Seladelpar, a selective peroxisome proliferator-activated receptor δ (PPARδ) agonist, improves markers of hepatic injury in human liver diseases, but histological improvement of nonalcoholic steatohepatitis (NASH) and liver fibrosis has been challenging with any single agent. To discover how complementary agents could work with seladelpar to achieve optimal outcomes, this study evaluated a variety of therapeutics (alone and in combination) in a mouse model of NASH. Mice on a high-fat amylin liver NASH (AMLN) diet were treated for 12 wk with seladelpar, GLP-1-R (glucagon-like peptide-1 receptor) agonist liraglutide, apoptosis signal-regulating kinase 1 (ASK1) inhibitor selonsertib, farnesoid X receptor (FXR) agonist obeticholic acid, and with seladelpar in combination with liraglutide or selonsertib. Seladelpar treatment markedly improved plasma markers of liver function. Seladelpar alone or in combination resulted in stark reductions in liver fibrosis (hydroxyproline, new collagen synthesis rate, mRNA indices of fibrosis, and fibrosis staining) compared with vehicle and the other single agents. Robust reductions in liver steatosis were also observed. Seladelpar produced a reorganization of metabolic gene expression, particularly for those genes promoting peroxisomal and mitochondrial lipid oxidation. In summary, substantial improvements in NASH and NASH-induced fibrosis were observed with seladelpar alone and in combination with liraglutide in this model. Broad gene expression analysis suggests seladelpar should be effective in concert with diverse mechanisms of action.NEW & NOTEWORTHY NASH is a chronic, progressive, and increasingly problematic liver disease that has been resistant to treatment with individual therapeutics. In this study using a diet-induced mouse model of NASH, we found that the PPARδ agonist seladelpar reduced fibrosis and NASH pathology alone and in combinations with a GLP-1-R agonist (liraglutide) or an ASK1 inhibitor (selonsertib). Liver transcriptome analysis comparing each agent and coadministration suggests seladelpar should be effective in combination with a variety of therapeutics.


Subject(s)
Acetates , Benzamides , Complementary Therapies , Imidazoles , Non-alcoholic Fatty Liver Disease , PPAR delta , Pyridines , Humans , Mice , Animals , Non-alcoholic Fatty Liver Disease/drug therapy , Non-alcoholic Fatty Liver Disease/metabolism , Liraglutide/pharmacology , Liraglutide/therapeutic use , PPAR delta/metabolism , PPAR delta/pharmacology , Liver/metabolism , Liver Cirrhosis/metabolism , Inflammation/metabolism , Mice, Inbred C57BL
2.
Adv Synth Catal ; 351(7-8): 999-1004, 2009 May 01.
Article in English | MEDLINE | ID: mdl-23966902

ABSTRACT

Unsaturated bicyclic endoperoxides are efficiently cyclopropanated with excess diazomethane in the presence of catalytic Pd(OAc)2 in a stereoselective manner. This method represents a new peroxide preserving transformation. Whereas the unsaturated endoperoxides in the [2.2.1] series are attacked by the carbene from the exo face, the analogs with larger bridges are preferentially attacked from the face syn to the peroxo bridge. Only in the case of the benzannelated [2.2.2] system the attack occurs exclusively from the face proximal to the benzene ring. Certain strained cyclopropanated endoperoxides are reduced by diazomethane to give cis-diols. 1-Methylfuran endoperoxide gives rise to cis-1-formyl-2-acetylcyclopropane in excellent yield.

3.
J Org Chem ; 73(17): 6943-5, 2008 Sep 05.
Article in English | MEDLINE | ID: mdl-18680344

ABSTRACT

5-Dialkylamino-4-pyrrolin-3-ones, available from cyclocondensation of amidines with dimethyl acetylenedicarboxylate (DMAD), undergo rapid singlet oxygenation to give highly functionalized ureas by way of a 1,2-dioxetane cleavage of the initially formed [2 + 2] cycloadducts. These latter compounds undergo cyclization to 2-oxazolidinones in MeOH. Catalytic hydrogenation of the ureas in EtOAc gives 2-oxazolinones. The DBU-DMAD adduct undergoes photooxygenation by an entirely different pathway to give a large ring heterocycle.


Subject(s)
Alkanes/chemistry , Amines/chemistry , Oxazoles/chemical synthesis , Oxygen/chemistry , Pyrroles/chemistry , Urea/chemical synthesis , Acetates/chemistry , Alkynes/chemistry , Amidines/chemistry , Catalysis , Cyclization , Heterocyclic Compounds/chemistry , Heterocyclic Compounds, 1-Ring , Hydrogenation , Methanol/chemistry , Models, Chemical , Oxazolidinones/chemical synthesis , Photochemistry , Solvents/chemistry
4.
Tetrahedron ; 62(46): 10676-10682, 2006 Nov 13.
Article in English | MEDLINE | ID: mdl-17998948

ABSTRACT

An unusual peroxide base promoted isomerization was uncovered. Saturated endoperoxides derived from fulvenes give rise to 2-vinyl-2-cyclopentenones upon treatment with DBU in CH(2)Cl(2) in a one-pot reaction. This methodology was applied to a convenient synthesis of dihydrojasmone. Moreover, functional groups placed on the side chain at C-6 participate in the base catalyzed isomerizations via conjugate attack at the enone moiety to give 2-cyclopentenones carrying oxygen heterocycles at C2.

SELECTION OF CITATIONS
SEARCH DETAIL
...